Skip to main content
Alok Khorana, MD, Oncology, Cleveland, OH, Cleveland Clinic

AlokA.KhoranaMD

Oncology Cleveland, OH

Gastrointestinal Cancer, Hematologic Oncology

Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Sondra and Stephen Hardis Endowed Chair in Oncology Research; Director GI Malignancies Program; Vice-Chair (Clinical Services), Taussig Cancer Inst, Cleveland Clinic

Dr. Khorana is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Khorana's full profile

Already have an account?

Summary

  • Alok A. Khorana, M.D., F.A.C.P, F.A.S.C.O, is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services of the Taussig Cancer Institute (part of Case Comprehensive Cancer Center) and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio. His clinical and translational research program focuses on predictive factors and drug development in cancer-associated thrombosis and gastrointestinal cancers and has been funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Hardis Family, the Porter Family Fund, VeloSano, the Cleveland Clinic Center for Excellence, the Scott Hamilton CARES Initiative, Stand Up To Cancer (Colorectal Cancer “Dream Team”) and the V Foundation.

    Dr. Khorana received his medical degree from Maharaja Sayajirao University’s Medical College in Baroda (now Vadodara, Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology/oncology at the University of Rochester, New York. He is a Fellow of the American College of Physicians and in 2018 was elected Fellow of the American Society of Clinical Oncology.

    Dr. Khorana is Past Chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGC), Chair of ASCO CPGC’s Pancreas Cancer Working Group, Co-Chair of ASCO CPGC’s Multisite Advisory Group and Co-Chair of the ASCO Guidelines Panel on Resectable Pancreas Cancer. He is currently Chair of the Medical and Scientific Advisory Board of the National Blood Clot Association. He has also served or serves on the ASCO Scientific Program Committee and multiple Guidelines/Guidance Panels.

Education & Training

  • University of Rochester
    University of RochesterFellowship, Hematology and Medical Oncology, 1999 - 2002
  • University at Buffalo
    University at BuffaloResidency, Internal Medicine, 1996 - 1999
  • Baroda Medical College
    Baroda Medical CollegeClass of 1995

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2013 - 2024
  • NY State Medical License
    NY State Medical License 2002 - 2014
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Maria and Sam Miller Professional Excellence Award for Scientific Achievement in Clinical Research Cleveland Clinic, 2019
  • Teacher of the Year (Medical Oncology) Cleveland Clinic, 2018
  • Sondra and Stephen Hardis Endowed Chair in Oncology Research Cleveland Clinic Foundation, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Do Patients with Pancreatic Body or Tail Cancer Benefit from Adjuvant Therapy?A Cohort Study  
    Alok Khorana, MD, ScienceDirect
  • An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index  
    Bewtra Meenakshi, Brensinger Colleen M, Tomov Vesselin T, Hoang Tram B, Sokach Carly E, Siegel Corey A, Lewis James D, Inflammatory Bowel Diseases, 6/1/2014
  • Diagnosis of Dry Eye Disease and Emerging Technologies  
    Zeev MS, Miller DD, Latkany R, Clin Opthalmol, 3/1/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis
    Alok A Khorana, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor MalignancyClinically Relevant Abstract
    Alok A Khorana, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade
    Alok A Khorana, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Cancer Associated Thrombosis Is Associated with Higher Mortality across All Khorana Score Risk Levels 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • What's New in VTE? Evaluating the Latest Evidence and Grades of Recommendation 
    60th American Society of Hematology Annual Meeting - 11/30/2018
  • Generosity: Normal and Pathological 
    Weill Cornell Medical School, New York, NY - 10/15/2014
  • Join now to see all

Other

  • Vaginal Hysterectomy. Videotape 
    Ling FW, Shull B, Hurt G, Stovall TG, Porges R, Lipscomb GH, Copyright: Council on Resident Education in Obstetrics and Gynecology
    1/1/1995

Press Mentions

  • New Take on an Old Problem: Tackling VTE with Biomarkers, Risk Models, and Novel Drugs
    New Take on an Old Problem: Tackling VTE with Biomarkers, Risk Models, and Novel DrugsMarch 1st, 2017
  • Cleveland Clinic-Led Study: Rivaroxaban Reduced Blood Clots and Related Death in Cancer Patients
    Cleveland Clinic-Led Study: Rivaroxaban Reduced Blood Clots and Related Death in Cancer PatientsDecember 4th, 2018
  • Cleveland Clinic Receives $4.7 Million Grant to Prevent Cancer-Associated Blood Clots
    Cleveland Clinic Receives $4.7 Million Grant to Prevent Cancer-Associated Blood ClotsAugust 8th, 2018
  • Join now to see all

Grant Support

  • Risk Factors For Venous Thromboembolism In Cancer Patients Receiving ChemotherapyNational Cancer Institute2006–2010

Hospital Affiliations